Claims for Patent: 11,154,509

Summary for Patent: 11,154,509

Title:	Methods for controlled release oral dosage of a vitamin D compound
Abstract:	A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
Inventor(s):	Bishop; Charles W. (Miami Beach, FL), Tabash; Samir P. (Whitby, CA), Agudoawu; Sammy A. (Mississauga, CA), White; Jay A. (Newmarket, CA), Crawford; Keith H. (Lone Tree, CO), Messner; Eric J. (Lake Forest, IL), Petkovich; P. Martin (Kingston, CA)
Assignee:	EIRGEN PHARMA LTD. (Waterford, IE) OPKO RENAL, LLC (Miami, FL)
Application Number:	15/726,046
Patent Claims:	1. A method of treating secondary hyperparathyroidism in a human patient having Stage 3 or 4 Chronic Kidney Disease (CKD), comprising administering to the patient an effective amount of a controlled release, oral dosage form of a vitamin D compound consisting of 25-hydroxyvitamin D to reduce the patient's serum parathyroid hormone level by at least 30% in combination with one or more calcium salts, bisphosphonates, calcimimetics, nicotinic acid, iron, phosphate binders, glycemic control agents, hypertension control agents, antineoplastic agents, inhibitors of CYP24, and inhibitors of other cytochrome P450 enzymes that can degrade vitamin D agents. 2. The method of claim 1, comprising administering to the patient a controlled release, oral dosage form of 25-hydroxyvitamin D in combination with one or more calcium salts. 3. The method of claim 1, comprising administering to the patient a controlled release, oral dosage form of 25-hydroxyvitamin D in combination with one or more bisphosphonates. 4. The method of claim 1, comprising administering to the patient a controlled release, oral dosage form of 25-hydroxyvitamin D in combination with one or more calcimimetics. 5. The method of claim 1, comprising administering to the patient a controlled release, oral dosage form of 25-hydroxyvitamin D in combination with nicotinic acid. 6. The method of claim 1, comprising administering to the patient a controlled release, oral dosage form of 25-hydroxyvitamin D in combination with iron. 7. The method of claim 1, comprising administering to the patient a controlled release, oral dosage form of 25-hydroxyvitamin D in combination with one or more phosphate binders. 8. The method of claim 1, comprising administering to the patient a controlled release, oral dosage form of 25-hydroxyvitamin D in combination with one or more glycemic control agents. 9. The method of claim 1, comprising administering to the patient a controlled release, oral dosage form of 25-hydroxyvitamin D in combination with one or more hypertension control agents. 10. The method of claim 1, comprising administering to the patient a controlled release, oral dosage form of 25-hydroxyvitamin D in combination with one or more antineoplastic agents. 11. The method of claim 1, comprising administering to the patient a controlled release, oral dosage form of 25-hydroxyvitamin D in combination with one or more inhibitors of CYP24. 12. The method of claim 1, comprising administering to the patient a controlled release, oral dosage form of 25-hydroxyvitamin D in combination with one or more inhibitors of other cytochrome P450 enzymes that can degrade vitamin D agents. 13. The method of claim 1, wherein the 25-hydroxyvitamin D comprises 25-hydroxyvitamin D.sub.3. 14. A method of treating secondary hyperparathyroidism in a human patient having Stage 3 or 4 Chronic Kidney Disease (CKD), comprising administering to the patient an effective amount of an sustained release, oral dosage form of a vitamin D compound consisting of 25-hydroxyvitamin D to reduce the patient's serum parathyroid hormone level by at least 30% while avoiding oversuppression of PTH. 15. The method of claim 14, wherein the patient has Stage 1-3 CKD, comprising avoiding a plasma iPTH level below 15 pg/mL. 16. The method of claim 14, wherein the patient has Stage 4 CKD, comprising avoiding a plasma iPTH below 30 pg/mL. 17. The method of claim 14, wherein the patient has Stage 5 CKD, comprising avoiding a plasma iPTH below 100 pg/mL.